24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Teva Pharmaceutical Industries
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
09:19
Intel CEO defiant as Trump calls for resignation
21:40
From stealth to $3.1 billion in less than a year
18:27
Historic $35 billion gas deal signed between Israel and Egypt
15:25
Trump calls for Intel CEO’s immediate resignation over China investments
More stories
Buzz
Most popular
Daily
Weekly
1
E-commerce shifts to AI: Yotpo lays off about 200 employees
2
Decart hits $3.1 billion valuation on $100 million raise to power real-time interactive AI
3
Andreessen Horowitz eyes elite IDF tech talent in rescheduled Israel visit
4
“Supersonic Growth”: Base44 set to hit $50M ARR just months after Wix acquisition
5
Tavily raises $20M Series A to build the Google of AI agents
More news
Teva Pharmaceutical Industries
6 stories about Teva Pharmaceutical Industries
Troubled Drugmaker Teva to Axe over 4,000 Jobs
23.11.17
|
Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
New Teva CEO Kåre Schultz to Relocate to Israel
17.10.17
|
Golan Hazani
Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month
Teva’s Stock Drops After Approval of Copaxone Competitors
08.10.17
|
Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
The Ten Challenges Facing Teva's New CEO
12.09.17
|
Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
Teva Sells IUD Business for $1.1 Billion
12.09.17
|
Lilach Baumer
Going forward, the company will focus on central nervous system and respiratory treatments, shedding its Women's Health and Oncology and Pain businesses
Teva Appoints Lundbeck's Schultz as CEO
11.09.17
|
Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Previous Articles